Indiana panel drops contentious requirement from voting bill
TOM DAVIES, Associated Press
FacebookTwitterEmail
INDIANAPOLIS (AP) A legislative committee has overhauled a contentious proposal to require Indiana voters to submit identification numbers with mail-in ballot applications.
Changes to the bill approved Thursday by the House elections committee will only require submission of a voter’s Indiana driver’s license number or the last four digits of their Social Security number with online mail ballot applications.
The panel deleted provisions that Republicans had pushed through the Senate making voters put such numbers on paper applications. Some election officials and voting rights advocates argued that would create a hurdle for voters since they likely wouldn’t know which number is on file with county election officials and could lead to applications being rejected.
Indiana panel drops contentious requirement from voting bill
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Indiana panel drops contentious requirement from voting bill
wlky.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wlky.com Daily Mail and Mail on Sunday newspapers.
(Provided Photo/Eli Lilly & Co.)
by: Alex Brown, Inside INdiana Business
Posted:
Mar 1, 2021 / 11:59 AM EST
INDIANAPOLIS (Inside INdiana Business) Indianapolis-based Eli Lilly and Co. is reporting positive results from two Phase 3 clinical trials of a drug designed to help people with type 2 diabetes. Lilly says tirzepatide led to “significant A1C and body weight reductions” in adults with the disease during the trials.
Lilly Diabetes President Mike Mason says the treatment continued to achieve “consistent efficacy and safety results” in adults with type 2 diabetes, regardless of how long they have had the disease.
“Significantly lowering A1C levels and weight are high priorities throughout the type 2 diabetes treatment journey, and the results we have seen from three SURPASS studies to date fuel our belief in tirzepatide’s ability to meet those needs,” said Mason.